232 related articles for article (PubMed ID: 27154743)
1. The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease.
Batchu SN; Brijmohan AS; Advani A
Clin Sci (Lond); 2016 Jun; 130(12):987-1003. PubMed ID: 27154743
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of HDAC6 activity in kidney diseases: a new perspective.
Ke B; Chen Y; Tu W; Ye T; Fang X; Yang L
Mol Med; 2018 Jun; 24(1):33. PubMed ID: 30134806
[TBL] [Abstract][Full Text] [Related]
3. HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases.
Li G; Jiang H; Chang M; Xie H; Hu L
J Neurol Sci; 2011 May; 304(1-2):1-8. PubMed ID: 21377170
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes.
Li Y; Shin D; Kwon SH
FEBS J; 2013 Feb; 280(3):775-93. PubMed ID: 23181831
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase 6 in health and disease.
Seidel C; Schnekenburger M; Dicato M; Diederich M
Epigenomics; 2015; 7(1):103-18. PubMed ID: 25687470
[TBL] [Abstract][Full Text] [Related]
6. Drugging the HDAC6-HSP90 interplay in malignant cells.
Krämer OH; Mahboobi S; Sellmer A
Trends Pharmacol Sci; 2014 Oct; 35(10):501-9. PubMed ID: 25234862
[TBL] [Abstract][Full Text] [Related]
7. Development and therapeutic impact of HDAC6-selective inhibitors.
Dallavalle S; Pisano C; Zunino F
Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
[TBL] [Abstract][Full Text] [Related]
8. Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
Kalin JH; Bergman JA
J Med Chem; 2013 Aug; 56(16):6297-313. PubMed ID: 23627282
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of selective histone deacetylase 3 inhibition.
Zhang L; Chen Y; Jiang Q; Song W; Zhang L
Eur J Med Chem; 2019 Jan; 162():534-542. PubMed ID: 30472601
[TBL] [Abstract][Full Text] [Related]
10. A novel class of anthraquinone-based HDAC6 inhibitors.
Song Y; Lim J; Seo YH
Eur J Med Chem; 2019 Feb; 164():263-272. PubMed ID: 30597327
[TBL] [Abstract][Full Text] [Related]
11. Structure, Functions and Selective Inhibitors of HDAC6.
Liang T; Fang H
Curr Top Med Chem; 2018; 18(28):2429-2447. PubMed ID: 30499393
[TBL] [Abstract][Full Text] [Related]
12. Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).
Simões-Pires CA; Bertrand P; Cuendet M
Expert Opin Ther Pat; 2017 Mar; 27(3):229-236. PubMed ID: 28092474
[TBL] [Abstract][Full Text] [Related]
13. A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
Zhang XH; Qin-Ma ; Wu HP; Khamis MY; Li YH; Ma LY; Liu HM
J Med Chem; 2021 Feb; 64(3):1362-1391. PubMed ID: 33523672
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of a selective HDAC6 inhibitor active in neuroblasts.
Zwick V; Simões-Pires CA; Nurisso A; Petit C; Dos Santos Passos C; Randazzo GM; Martinet N; Bertrand P; Cuendet M
Bioorg Med Chem Lett; 2016 Oct; 26(20):4955-4959. PubMed ID: 27650925
[TBL] [Abstract][Full Text] [Related]
15. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
Qin HT; Li HQ; Liu F
Expert Opin Ther Pat; 2017 May; 27(5):621-636. PubMed ID: 28033734
[TBL] [Abstract][Full Text] [Related]
16. A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019).
Shen S; Kozikowski AP
Expert Opin Ther Pat; 2020 Feb; 30(2):121-136. PubMed ID: 31865813
[No Abstract] [Full Text] [Related]
17. Ciliopathies: Does HDAC6 Represent a New Therapeutic Target?
Yu F; Ran J; Zhou J
Trends Pharmacol Sci; 2016 Feb; 37(2):114-119. PubMed ID: 26651415
[TBL] [Abstract][Full Text] [Related]
18. The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.
Cosenza M; Pozzi S
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30096875
[TBL] [Abstract][Full Text] [Related]
19. Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration.
Richter-Landsberg C; Leyk J
Acta Neuropathol; 2013 Dec; 126(6):793-807. PubMed ID: 23912309
[TBL] [Abstract][Full Text] [Related]
20. HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer.
McConkey DJ; White M; Yan W
Adv Cancer Res; 2012; 116():131-63. PubMed ID: 23088870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
